Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND)
Biomolecules · 15.05.2026 · 16 (5) · 728
DOI: 10.3390/biom16050728 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.05.2026. Verfasst von Riddhi Trivedi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA. Hauptthemen laut MEDLINE: HIV Infections, AIDS Dementia Complex, Anti-HIV Agents, Neurocognitive Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health Clinical Center, NIA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
HIV-associated neurocognitive disorders (HAND) arise from HIV infection of the central nervous system, resulting in chronic neuroinflammation and progressive neuronal damage that impair cognitive, motor, and behavioral functions. Clinically, HAND encompasses a spectrum of neurological impairments ranging from asymptomatic neurocognitive impairment to severe HIV-associated dementia. Despite the widespread use of combination antiretroviral therapy (cART) and significant improvements in the life expectancy of people living with HIV, HAND remains prevalent and continues to pose a major clinical challenge. One of the primary limitations of cART is the limited penetration of many antiretroviral drugs across the blood–brain barrier (BBB), thereby allowing the persistence of viral reservoirs within the CNS and contributing to sustained neuroinflammation and neuronal damage. To address these challenges, novel nanotherapeutic strategies have been developed to enhance the delivery of antiretroviral agents to the brain. These approaches include targeted delivery systems and the co-delivery of therapeutics across the BBB through mechanisms such as receptor-mediated transcytosis and other transport pathways. In this review, we discuss the pathophysiological challenges associated with HAND and recent advances in nanotherapeutic approaches designed to improve treatment efficacy. We also discuss the current state of the art in vitro and in vivo models used to test the efficacy of these advanced therapeutics. Finally, we outline the remaining challenges and future prospects for the development of nanotherapeutics to improve the treatment of HAND.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA.
ORCID-Profile: Riddhi Trivedi, Avinash Gothwal, Buddhadev Layek, Jagdish Singh
Förderung
- National Institutes of Health Clinical Center
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2026). Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND). Biomolecules, 16(5), 728. https://doi.org/10.3390/biom16050728
Vancouver
Trivedi R, Gothwal A, Layek B, Singh J. Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND). Biomolecules. 2026;16(5):728. doi:10.3390/biom16050728
BibTeX
@article{Trivedi2026,
author = {Trivedi, Riddhi and Gothwal, Avinash and Layek, Buddhadev and Singh, Jagdish},
title = {Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND)},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {5},
pages = {728},
doi = {10.3390/biom16050728}
}
EUVIMED